abstract: Invasion of uterine tissues by extravillous trophoblast cells (EVT) is essential for successful human pregnancy. EVT invasion is tightly regulated by a number of factors, including growth factors and cytokines, but the mechanisms that underlie their regulatory effect remain poorly understood. Interleukin (IL)-6 has been suggested to play a role in controlling EVT invasion. We hypothesized that IL-6 produced by cells in uterine decidua would regulate EVT invasiveness via IL-6Ra and gp130 receptors expressed by trophoblast cells. The effect of IL-6 on EVT signalling and cytokine production was also studied. Supernatants from disaggregated 'total' decidual cells, CD8
Introduction
Invasion of maternal uterine tissues and spiral arteries by extravillous trophoblast cells (EVT) is crucial for the establishment of successful human pregnancy (Pijnenborg et al., 1983) . EVT cells derive from differentiation of cytotrophoblast (CTB) cells of the developing placenta (Vicovac and Aplin, 1996) , which acquire an invasive phenotype and infiltrate the maternal uterine tissue by two separate pathways: endovascular trophoblast cells migrate in a retrograde direction within the lumen of uterine spiral arteries, whereas interstitial EVT invasion requires an active biochemical process with attachment of CTB cell columns to the uterus and EVT migration through decidua and inner myometrium associated with proteolytic degradation of extracellular matrix components (Lash et al., 2005) . EVT invasion is co-ordinated in a spatial and temporal manner and disruptions in this tight control are associated with various pregnancy complications including early and late miscarriage (Khong et al., 1987; Hustin et al., 1990; Ball et al., 2006) , pre-eclampsia (Pijnenborg et al., 1991) and fetal growth restriction (Khong et al., 1986) . Despite its importance for successful pregnancy, the factors that control EVT invasion are poorly understood, although it is likely that decidual factors play an important role (Fitzgerald et al., 2008) .
Interleukin (IL)-6 is a small multifunctional glycoprotein that is involved in defence mechanisms, haematopoiesis and oncogenesis. IL-6 signals through a receptor system consisting of a 130 kDa protein gp130 (a common co-receptor) and an 80 kDa protein IL-6Ra (an IL-6 specific receptor), and the signal transducer and activators of transcription 3 (STAT3) pathway or the mitogen-activated protein kinase pathway (Corvinus et al., 2003; Fitzgerald et al., 2005; Pollheimer and Knofler, 2005) . IL-6 is expressed in a variety of malignant tumours (Kanazawa et al., 2007) , and increases the invasive potential of head and neck cell carcinomas in vitro (Nishino et al., 1998; Kanazawa et al., 2007) , and IL-6 secreted from breast adipose stromal cells promotes migration and invasion of breast tumour cells in vitro (Walter et al., 2009) . IL-6 is expressed in the human endometrium throughout the menstrual cycle and in early pregnancy. protein and mRNA have been localized in mid-secretory phase endometrium predominantly in glandular and luminal epithelial cells (Tabibzadeh et al., 1995) . Despite extensive documentation of its presence in uteroplacental tissues, little is known about the functional effects of IL-6 on trophoblast, precise sites of IL-6 production and mechanisms of IL-6 induced signalling in the trophoblast.
Recent studies provide some evidence that IL-6 may play a role in EVT invasion. Meisser et al. (1999) reported induction of trophoblast matrix metalloproteinase (MMP)-2 and MMP-9 activity by IL-6, although synthesis of MMP was not induced. Jovanović and Vićovac (2009) reported that IL-6 increased migration and the invasive potential of the EVT cell line HTR-8/SVneo due to up-regulation of trophoblast integrins a 1 , a 5 and b 5 that bind to the components within the extracellular matrix. In addition, Dubrinsky et al. (2010) reported that inhibition of endogenous IL-6 in JEG-3 choriocarcinoma cells inhibited migration and invasion.
Although the role of IL-6 has been widely studied in neoplastic processes, there is limited information on its role in human uteroplacental tissues. IL-6 is widely expressed in the endometrium at implantation, increased levels of placental IL-6 have been detected in women suffering pre-eclampsia (Zhao et al., 2008) and sera from women suffering from recurrent miscarriage have been reported to have increased levels of soluble IL-6 receptor and IL-6 compared with controls (Arruvito et al., 2009) . In contrast, inadequate IL-6 mRNA production has been reported in the endometrium of women suffering from recurrent miscarriage (Jasper et al., 2007) . In the current study, we hypothesized that (i) IL-6 and its receptors are expressed in the placental bed of early human pregnancy; (ii) IL-6 stimulates EVT invasion; (iii) IL-6 stimulates EVT cell signalling pathways and production of other cytokines.
Materials and Methods

Sample collection
Placenta and decidua were obtained with informed consent from women undergoing elective surgical pregnancy termination at the Royal Victoria Infirmary, Newcastle upon Tyne, UK at 8 -10 and 12 -14 weeks gestational age (n ¼ 10 each gestational age group). Samples were collected into sterile containers and transported to the laboratory where placenta and decidua were separated based on macroscopic appearance and washed in phosphate-buffered saline (pH 7.4) to remove excess blood. Placental bed biopsies were obtained as previously described (Robson et al., 2002) after termination of pregnancy at 8 -10, 12 -14 and 16 -20 weeks gestational age (n ¼ 5 each age group). Tissue was fixed in 10% neutral-buffered formalin for 24 -48 h and embedded in paraffin wax or snap frozen in liquid nitrogen cooled isopentane (Sigma Chemical Co., Poole, UK). Serial 3 and 5 mm sections were cut for paraffin and frozen samples, respectively.
Isolation of total decidual and CD56
1 cells
Total decidual, CD56 + uterine natural killer (uNK) cell, CD8 + T cell,
CD10
+ stromal cell and CD14 + macrophage cultures were prepared as previously described (Vassiliadou and Bulmer, 1998) . Briefly, decidual tissue was minced, subjected to DNase/collagenase enzymatic digestion and incubated overnight at 378C in complete RPMI 1640 medium [containing 10% fetal bovine serum (FBS), 1000 U/ml penicillin, 1 mg/ml streptomycin and 2 mM L-glutamine; all from Sigma Chemical Co.] to allow cells to adhere. The cells were either used as a total unfractionated decidual cell suspension or different cell populations were isolated by positive selection with anti-CD56 (Coulter, High Wycombe, UK), anti-CD10 (Leica, Newcastle upon Tyne, UK) or anti-CD8 (Leica) and immunomagnetic beads (MidiMACS; Miltenyi Biotec., Surrey, UK) as previously described (Vassiliadou and Bulmer, 1998 
Isolation of EVT and villous CTB cells
EVT and villous CTB cells were isolated from placenta at 8 -10 and 12 -14 weeks gestational age, using a modification of a method described by Tarrade et al. (2001) and Lash et al. (2010) . Placental chorionic villi were washed thoroughly in Hanks Balanced Salt Solution (Mg/Ca free) to remove excess red blood cells. Chorionic villi were dissected from the placental membrane, minced to 0.5 mm 3 and enzymatically digested for 30 min without agitation at 378C in 0.025% trypsin (BD Biosciences, Franklin Lake, NJ, USA), 0.5 mg DNase I (Sigma Chemical Co.). Supernatant containing a single cell suspension was removed and the remaining chorionic villi were subjected to a second digestion as above. The single cell suspensions from digests 1 and 2 (EVT) were combined in 1 ml FBS (Sigma Chemical Co.) to inhibit residual enzymes and centrifuged. The cell pellet was then resuspended in Dulbecco's Modified Eagle Medium:F12 (DMEM:F12). The remaining chorionic villi were digested for a third time with agitation (CTB). Cell suspensions were layered onto a percoll gradient (10-55% percoll), centrifuged (1200g, 30 min, no brake) and EVT or CTB cell layers (35-45% percoll) removed, diluted in excess medium, centrifuged at 300g for 7 min and resuspended in complete medium (DMEM:F12, 10% FBS, 1000 U/ml penicillin, 1 mg/ml streptomycin, 2 mM L-glutamine and 1.5 mg amphotericin B; all from Sigma Chemical Co.). Following isolation 1 × 10 6 cells/ml were stored at 2808C for RNA isolation (t ¼ 0). EVT (2 × 10 5 /600 ml/well) were cultured in a 24-well plate coated with growth factor reduced Matrigel w (BD Biosciences) and CTB (2 × 10 5 /600 ml/well) were cultured in a 24-well plate coated with fibronectin (Sigma Chemical Co.). Isolated EVT and CTB cells were cultured for 24 h at 378C in a 5% CO 2 incubator and whole cell lysates and cell culture supernatants were harvested and stored at 2808C. Isolated EVT and CTB were consistently .95% pure as assessed by immunohistochemistry of cell smears for HLA-G and cytokeratin 7 (Lash et al., 2005 . Any sample that had ,95% purity was not used in the current study. Cell yield for both trophoblast populations was relatively consistent (EVT, range 0.7 -1.3 × 10 6 cells, median 0.9 × 10 6 cells; CTB, range 0.8 -1.5 × 10 6 cells, median 1.05 × 10 6 cells).
HTR-8/SVneo cell line
The EVT cell line HTR-8/SVneo (Graham et al., 1993) was kindly provided by Prof. Charles H. Graham, Queen's University, Kingston, Ontario, Canada. Cells were maintained at 378C, 5% CO 2 in complete RPMI 1640 medium and passages 10 -50 were used. HTR-8/SVneo cells have been reported to be integrin a6 negative, but positive for integrin a1, cytokeratin 7 and HLA-G when grown on Matrigel (Lash et al., 2007) .
Immunohistochemistry
Placental bed biopsies and placenta were used for localization of IL-6 and IL-6 receptors. Paraffin sections were dewaxed in xylene, rehydrated and incubated in 1% H 2 O 2 in methanol for 10 min to block endogenous peroxidase activity; frozen sections did not require pretreatment. All washes were performed in 0.15 M Tris buffered 0.05 M saline (TBS, pH 7.6). For any given antibody, all tissue sections were immunostained in the same staining run to avoid day-to-day variation. The immunostaining procedure has been described in detail previously (Pongcharoen et al., 2004) . Source, dilution and pretreatment for all primary antibodies are detailed in Table 1 . Detection was done routinely with mouse Vectorstain Elite ABC Kit with the exception of IL-6 which was detected using the polymer-based Immpress Kit (Vector Laboratories, Peterborough, UK). The reaction was developed with 3,3 ′ -diaminobenzidine (DAB; Sigma Chemical Co.) containing 0.01% H 2 O 2 for 2 -3 min to give a brown reaction product. The sections were lightly counterstained with Mayer's haematoxylin for 1 min, dehydrated, cleared in xylene and mounted with DPX synthetic resin (Raymond A. Lamb Ltd., London, UK). Positive controls were included in each staining run; negative controls were performed for each sample and included replacement of the primary antibody by appropriate non-immune serum.
Immunocytochemistry
EVT and HTR-8/SVneo cells (1 × 10 5 cells/ml) were cultured overnight at 378C, 5% CO 2 in 8-well chamber slides (BD Biosciences). After incubation, the chamber was removed and the slide fixed in acetone for 10 min. The cells were incubated with appropriately diluted antibodies against gp130 and IL-6Ra (Table 1) for 2 h. The reaction was developed using DAB and slides were then counterstained with haematoxylin and mounted in DPX. Cell smears were also prepared from primary EVT cells and HTR-8/SVneo cells and immunostained to confirm receptor expression. Negative controls were performed in all experiments with replacement of primary antibody by non-immune serum.
IL-6 ELISA
IL-6 protein levels in supernatants (t ¼ 24 h) of total decidual isolates, CD56 + uNK cell enriched isolates, CD8 + T cell enriched isolates, CD14 + macrophage enriched isolates, CD10 stromal cell enriched isolates, CTB and EVT (n ¼ 10 for each cell type, 8 -10 and 12-14 weeks gestational age) were determined using a human IL-6 ELISA Development Kit (Peprotech EC Ltd., London, UK) according to the manufacturer's instructions.
RT-PCR for IL-6 expression
Total RNA was extracted from the different cell populations (t ¼ 0; 8-10 weeks gestation n ¼ 5, 12 -14 weeks gestation n ¼ 4) using TRIzol, according to the manufacturer's instructions (Sigma Chemical Co.) (Lash et al., 2006) . RNA was quantified using a nanodrop instrument (ND-1000 V3, Labtech Int., UK) and 400 ng reverse-transcribed into cDNA using Superscript III according to the manufacturer's instructions (InVitrogen, Paisley, UK). Two microliters of cDNA was used in the PCR reaction along with IL-6 primer pair (IL-6 Assay on demand, Applied Biosystems, Carlsbad, CA, USA) or glyceraldehyde-3-phosphatedehydrogenase (GAPDH) primer pair (GAPDH Assay on Demand, Applied Biosystems). Real-time RT -PCR (ABI7000; Applied Biosystems) was performed according to the manufacturer's instructions. To confirm amplicon length, some of the PCR products were separated on 1% agarose gel, soaked in ethidium bromide, visualized using an UV transluminator and the image captured using Alpha Imager software package. The expected band sizes were 95 and 250 bp for IL-6 and GAPDH, respectively.
Western blot analysis for detection of IL-6 receptors IL-6 receptor expression was investigated by western blot. HTR-8/SVneo cells and EVT were cultured for 24 h, trypsinized, resuspended in 50 mM HEPES protein extraction buffer containing 1% protease inhibitor cocktail and stored at 2208C until required. Twenty micrograms of protein (determined with a Bio-Rad DC protein assay, Bio-Rad Laboratories, Hercules, CA, USA) was subjected to SDS -PAGE, resolved proteins transferred to Immobilon-P membranes (Millipore, Bedford, MA, USA) and then blocked overnight in 5% milk blocking solution (TBS and 0.05% Tween-20 (TBS-T) and 5% dried non-fat milk) at 48C. The membrane was incubated with anti-IL-6Ra (1:200, 2 h, Santa Cruz Biochemicals, Santa Cruz, CA, USA). The membranes were washed in TBS-T for 3 × 5 min, incubated with horse-radish peroxidase-conjugated goat antimouse secondary antibody (1:3000, 1 h, Bio-Rad) and then washed in TBS-T for 3 × 5 min. After initial analysis, membranes were re-probed for anti-Gb loading control (1:5000, Santa Cruz). All antibodies were subsequently developed using chemiluminescence (Thermo Scientific, Rockford, IL, USA) according to the manufacturer's instructions and recorded by X-ray Kodak Scientific Imaging film (Sigma Chemical Co.).
Invasion assay
Placental samples (8-10 weeks gestational age; n ¼ 5) were prepared for explant cultures and Matrigel w invasion assays performed as previously described (Lash et al., 2005 IL-6 and extravillous trophoblast invasion was investigated by the addition of exogenous IL-6 and sIL-6Ra reconstituted in 10 nM acetic acid (1, 10 ng/ml IL-6, 20 ng/ml sIL-6Ra; 10 ng/ml IL-6 + 20 ng/ml sIL-6Ra; n ¼ 5 each concentration/combination) including a medium control containing 1 ml/ml acetic acid. A combination of cytokine and soluble cytokine receptor was used because of the agonist effects of sIL-6Ra. The role of endogenous IL-6 was investigated by addition of a neutralizing antibody (rabbit anti-human IL-6, 1 mg/ml). All cytokines and antibodies were purchased from Peprotech EC, (London, UK). Assays were performed in duplicate for each sample and repeated on five separate occasions. Data are expressed as the mean invasion index (+SEM) where the level of invasion was normalized to the control within each experiment. 1 × 10 5 HTR-8/SVneo cells were added to growth factor reduced Matrigel w (BD Biosciences) coated 8.0 mm inserts and treated with 1 ng/ml IL-6, 10 ng/ml IL-6, 20 ng/ml sIL-6Ra or 20 ng/ml sIL-6Ra and 10 ng/ml IL-6 in acetic acid (all from Peprotech EC, n ¼ 3 each concentration) including a medium control containing 1 ml/ml acetic acid. Inserts were incubated at 378C in 5% CO 2 for 48 h and then stained, mounted and assessed as for placental explants. Each invasion assay was performed in triplicate on three separate occasions. Data are expressed as the mean invasion index (+SEM) where the level of invasion was normalized to the control within each experiment.
Phosphokinase array
Isolated EVT were cultured on growth factor reduced Matrigel w (BD Biosciences) overnight prior to treatment with 10 ng/ml human recombinant IL-6 (Peprotech EC) or 10 nM acetic acid medium (control) for 10 min at 378C in 5% CO 2 . Whole cell lysates were prepared using the lysis buffer provided. A Bio-Rad DC total protein assay was performed to determine protein concentration of the cellular extract. Pooled EVT lysates (2-3 samples) were used at a concentration of 250 mg total protein for each experiment. HTR-8/SVneo cells were grown to 100% confluence prior to treatment and used at a concentration of 300 mg total protein concentration for each experiment. Following the protein assay, cellular extracts were stored at 2808C until required for use. The phosphokinase array was performed according to the manufacturer's instructions (Human Phospho-Kinase Array Kit, R&D systems, Inc. Minneapolis, MN, USA). The membranes were then developed using chemiluminescence (Thermo Scientific) and exposed by X-ray KODAK film (Sigma Chemical Co.) for 10 min. The array signals from the X-ray film were scanned and images were quantified using Adobe Photoshop TM by a mean spot pixel density counting method. Signal values were exported to Microsoft Excel for analysis. Corresponding signals were compared to determine the relative change in phosphorylated kinase proteins between untreated and treated cells. Data from the array were normalized to control values to facilitate comparison between each experiment (n ¼ 3 for both EVT and HTR-8/SVneo lysates).
FASTQuant w array
Isolated EVT cells (8 -14 weeks' gestation; n ¼ 4) were cultured on growth factor reduced Matrigel w (BD Biosciences) overnight, treated with 10 ng/ml human recombinant IL-6 or 10 nM acetic acid medium (control) for 24 h at 378C, 5% CO 2 . FASTQuant w multiplex arrays (human II, TH1/2 and angiogenesis kits) were used according to the manufacturer's instructions (FASTQuant w , GE Healthcare, Chalfont St Giles, UK) to determine whether IL-6 had any effect on EVT secretion of cytokines and angiogenic growth factors. The slides were imaged using an Axon GenePix scanner and data analysis was performed by the ArrayVision TM FAST w software.
Statistical analysis
Data are presented as mean + SEM. Data were analysed using StatView software package (Abacus Concepts, Inc., Berkley, CA, USA). Statistical significance was determined using one-way analysis of variance, followed by Fisher's post hoc analysis. Wilcoxon non-parametric tests were performed for non-normal skewed distribution of data and t-test was used when only two sets of data were compared and data were normally distributed. Differences were considered statistically significant at P , 0.05.
Results
IL-6 production in uteroplacental tissues
To determine the potential decidual cell source of IL-6 secretion by total unfractionated decidual cell isolates, CD56 + uNK cells, CD10 + stromal cells, CD14 + macrophages, CD8 + T cells, CTB and EVT was assessed in 24 h cell culture supernatants of cells isolated from 8 to 10 and 12 to14 weeks gestational age (n ¼ 10 each group). IL-6 was secreted by each of the enriched cell types determined by ELISA (Fig. 1A) . Levels of IL-6 secreted by CD10 + stromal cells, Figure 1 (A) ELISA data showing levels of IL-6 secreted from TDC, CD8 + T cell, CD10 + decidual stromal cell, CD14 + macrophage, CD56 + uNK cell, CTB and EVT cell supernatants at 8 -10
and 12 -14 weeks gestational age (n ¼ 10 for each cell type and gestational age group). Data are expressed as mean + SEM (pg/ml) of IL-6 protein detected. (B) Representative RT-PCR illustrating IL-6 mRNA expression at 95 bp (left) at 8 -10 weeks' and 12 -14 weeks' gestational age (T, total decidual cell isolates; uNK, uNK cell isolates). GAPDH mRNA expression at 250 bp (right) is shown as loading control for the experiment.
CTB and EVT were higher at 12 -14 compared with 8 -10 weeks' gestation (CD10 + stromal cells P ¼ 0.005; CTB P ¼ 0.02; EVT P ¼ 0.003; Fig. 1A ).
To confirm IL-6 expression, RT-PCR was performed on TDC, CD56 + uNK cell, CD14 + macrophages, CD8 + T cells, EVT and CTB isolates from 8 to 10 (n ¼ 5) and 12 to 14 weeks' gestation (n ¼ 4). IL-6 RNA transcripts were detected in all samples as determined by real-time RT -PCR. Representative PCR products for TDC and uNK cell isolates were also run on an agarose gel (Fig. 1B) .
IL-6 and IL-6 receptor immunolocalization
Representative immunostaining is shown in Fig. 2 . IL-6 immunostaining was widespread throughout the placental bed at all gestational ages and could be seen immunolocalized with leukocytes, stromal cells and EVT (Fig. 2A) . The IL-6 receptors gp130 (Fig. 2B ) and IL-6Ra (Fig. 2C) were both immunolocalized to EVT within the placental bed at 8 -10, 12-14 and 16 -20 weeks gestational age. IL-6Ra, and to a lesser extent gp130, were also immunolocalized to spiral arteries within the placental bed. IL-6 was also immunolocalized to syncytiotrophoblast, villous CTB and EVT cells in the cell columns of the placenta at all gestational ages investigated ( Fig. 2E-H ). IL-6 immunostaining was most notable in the distal portions of the EVT cell columns (Fig. 2G) . Immunocytochemistry of isolated EVT and HTR-8/SVneo cells in culture demonstrated that both cell types express the IL-6 receptors, gp130 and IL-6Ra (Fig. 2I -L) . Western blot analysis was performed to confirm IL-6 receptor expression by trophoblast cells and specificity of the IL-6Ra antibody. The 80 kDa full length IL-6Ra protein was expressed in both isolated EVT and HTR-8/SVneo cells ( Fig. 2O ; n ¼ 3 both cell types) confirming expression of IL-6Ra by trophoblast cells. The house-keeping gene Gb (36 kDa) was used as a loading control for the experiment.
Functional effects of IL-6 on trophoblast cells
Invasion assays
Addition of exogenous IL-6 had no effect on the invasiveness of either HTR-8/SVneo cells (Fig. 3A) or EVT cells from first trimester (8-10 weeks) placental explants (Fig. 3B) . Unlike most soluble receptors, sIL-6Ra potentiates the action of IL-6 and facilitates its binding to the IL-6Ra/gp130 receptor complex. Addition of sIL-6Ra had no effect on invasiveness of either HTR-8/SVneo cells or EVT from placental explants, demonstrating that endogenous IL-6 produced by the trophoblast cells themselves does not contribute to invasion. Addition of IL-6 neutralizing antibody also had no effect on EVT cell invasion, again suggesting that endogenous IL-6 secreted from the EVT cells does not play a role in their invasiveness (Fig. 3B ).
Phospho-kinase array
A kinase array that measures phosphorylation status for 46 kinase proteins involved in cellular signalling cascades was performed to determine whether IL-6 signalled in trophoblast cells. IL-6 stimulated phosphorylation of 9 of the 46 signalling proteins investigated in isolated primary EVT (n ¼ 3) (Supplementary data, Fig. S1, A -I) . The proteins in primary EVT that were most highly stimulated upon treatment were: Src P ¼ 0.01; Jun P ¼ 0.01 and STAT3 P ¼ 0.02. IL-6 decreased stimulation of b-catenin (P ¼ 0.02), STAT1 (P ¼ 0.04) and STAT4 (P ¼ 0.002) and increased the stimulation of STAT5a (P ¼ 0.006) from the 46 different kinase proteins in the HTR-8/ SVneo cell line (Supplementary data, Fig. S2 ). However, signal spot intensity was very high in all replicates, indicating that HTR-8/SVneo cell signalling proteins are constitutively stimulated regardless of cytokine treatment. When a Bonferroni correction (P , 0.001) was performed to take into account multiple comparisons, statistically significant differences were lost.
FAST Quant w array
The effect of 10 ng/ml IL-6 on EVT cytokine and angiogenic growth factor production by primary EVT cells was determined at 8-10 weeks gestational age. Treatment of EVT cells with IL-6 decreased secretion of RANTES (regulated upon activation, normal t-cell expressed and secreted) (P ¼ 0.03, Fig. 4A ). EVT expression of RANTES mRNA was also reduced after treatment with IL-6 using realtime RT -PCR (P ¼ 0.05, Fig. 4B ; n ¼ 4).
Discussion
In the present study, we have demonstrated high levels of IL-6 in uteroplacental tissues in early pregnancy, with uNK cells being one decidual cell type that produces this cytokine. IL-6 production from decidual stromal cells, CTB and EVT cells increases with gestational age. Using both placental villous explants and a trophoblast cell line, HTR-8/SVneo, there was no effect of IL-6 on trophoblast invasion. However, there was some evidence that IL-6 may be able to stimulate signalling pathways in isolated EVT cells and affect production of cytokines involved in migratory function which may have other roles in trophoblast biology such as regulating hCG secretion and EVT differentiation. This study provides further evidence that high levels of IL-6 are expressed in early human pregnancy in agreement with previous reports. Decidual stromal cells, uNK cells, CD8
+ T cells, macrophages, CTB and EVT are all producers of this cytokine, with production increasing with gestational age between 8-10 and 12-14 weeks in decidual stromal cells as well as both populations of trophoblast cells. Production of IL-6 by a wide range of uteroplacental cell types has not yet been fully reported and this study shows for the first time that secretion of IL-6 by some cell types in uteroplacental tissues varies with gestational age. Although uNK cells are a source of IL-6, they are not the sole or even the main producer of this cytokine. The decidua includes a variety of cell populations including T cells, macrophages, stromal and epithelial cells that all contribute to IL-6 production, explaining the high IL-6 levels secreted by TDC isolates and as demonstrated by widespread immunostaining in the placental bed biopsies. Interestingly, the sum of IL-6 secretion levels from the different isolated cells was lower than the secreted levels of the total decidual isolates, suggesting that other cell types may contribute to IL-6 production or that different cell types work synergistically to enhance IL-6 production. IL-6 is also produced by trophoblast cells; IL-6 production has been demonstrated in various choriocarcinoma cells, including BeWo, Jar and JEG-3 cells, as well as the EVT-like cell line HTR-8/SVneo (Jovanović and Vićovac, 2009) . We have now demonstrated IL-6 production in both primary CTB and EVT isolates at 8-14 weeks gestation, with levels increasing with gestational age. Although it has been documented that IL-6 is expressed in human uteroplacental tissues, little information exists on its function in early human pregnancy. There is some evidence suggesting that IL-6 plays an important role in implantation and early placental development. In humans, Jasper et al. (2007) reported increased endometrial IL-6 mRNA levels in women suffering recurrent miscarriage. Greer et al. (1994) also recorded a significant increase in serum IL-6 concentrations in pre-eclamptic women compared with normal pregnant women. IL-6 has also been related to infertility in humans, with significantly increased serum concentrations of IL-6 being reported in infertile compared with fertile women (Demir et al., 2009) .
It has been postulated that one of the main roles of IL-6 in uteroplacental tissues is regulation of trophoblast invasion. Although IL-6 is widely associated with studies involving progression of certain cancers and is known to have an effect on the invasiveness of cancer cells, there is limited information on its role in trophoblast invasion. Despite expression of IL-6 receptors by primary isolated EVT and HTR-8/SVneo cells, neither exogenous nor endogenous IL-6 had any effect on trophoblast invasion in the present study. In contrast, Jovanović and Vićovac (2009) demonstrated an increase in the invasive potential of first trimester villous CTB cells and HTR-8/SVneo cells after IL-6 treatment in vitro. This discrepancy could be explained by the differences in the cell type used; in the present study placental villous explants from which EVT are derived were used, whereas Jovanović and Vićovac (2009) studied isolated villous CTB cells. The varying results between the two studies with HTR-8/SVneo cells may be due to their differing passage number which could account for changes in cellular function. Quantification methods also differed between the studies; Jovanović and Vićovac (2009) counted selected fields of the membrane inserts and included occupied pores within their cell counts, whereas in the present study, only cells that had completely invaded through the pores were counted in the whole insert. In addition, Dubrinsky et al. (2010) used silencing RNA technology to inhibit IL-6 expression in JEG-3 choriocarcinoma cells which inhibited both cellular migration and invasion, suggesting that endogenous IL-6 does contribute to regulation of cell invasion in this cell type.
There is increasing evidence that HTR-8/SVneo cells are an imperfect model for EVT as they respond differently to oxygen concentrations compared with primary EVT, and they do not express the integrins and non-classical major histocompatibility complex class I molecules such as HLA-G that are typical of EVT unless cultured on extracellular matrix (Lash et al., 2007; Apps et al., 2009) . Recent data (Bilban et al., 2010) have demonstrated differences in gene expression profiles of integrins, proteases, hormones and growth factors between trophoblast cell lines and primary CTB and EVT. Indeed, HTR-8/SVneo cells were most distantly related to primary cells and therefore are not an ideal model for EVT. The effect of IL-6 on trophoblast invasion using primary EVT isolates or placental explants has not been previously reported but the results obtained from this study suggest that IL-6 does not play a role in regulating EVT invasion in early pregnancy. In accordance with this, Cohen et al. (2010) concluded that decidual cells, which are producers of IL-6, do not play a major role in regulating CTB invasion in vitro using a decidua/EVT co-culture method. In contrast, CTB cells increased the invasiveness of decidual cells by increasing their secretion of MMPs.
Although we have demonstrated that IL-6 did not affect trophoblast invasion, the kinase profile array performed in this study demonstrated stimulation of nine signalling pathway kinase proteins in isolated primary EVT by exogenous IL-6, although significance was lost after correction for multiple testing. Therefore, the effect of IL-6 on stimulation of these proteins needs to be verified using specific assays for each protein. These signalling proteins were constitutively phosphorylated in HTR-8/SVneo cells regardless of IL-6 treatment, suggesting constant activation and providing further evidence that this cell line is an imperfect model for EVT. Indeed, three of the four proteins were less phosphorylated after IL-6 treatment of HTR-8/SVneo cells. In isolated EVT, the proteins that were most highly phosphorylated by IL-6 were: Src protein, a proto-oncogenic tyrosine kinase which is reported to be involved in embryonic development and cell growth; STAT3 a transcriptional activator of transcription of genes involved in cellular growth and proliferation; and c-Jun an early transcription factor that interacts directly with specific target DNA sequences to regulate gene expression. STAT3 is a major downstream protein involved in IL-6 signalling, and molecular studies have shown that STAT3 is a contributor to EVT invasive capacities (Fitzgerald et al., 2005) . IL-6 may therefore up-regulate genes involved in trophoblast growth or differentiation, although further investigations are required to gain insight into the specific role for this cytokine in trophoblast function. Figure 3 The effect of IL-6, sIL-6Ra and neutralizing antibody on invasion of (A) HTR-8/SVneo cells (n ¼ 3) and (B) EVT cells from isolated villous explants at 8 -10 weeks gestational age (n ¼ 5) in a Matrigel invasion assay. Data are expressed as invasion index normalized to the control for each experiment (mean + SEM for each experiment).
IL-6 and extravillous trophoblast invasion
Demonstration of IL-6 receptors on EVT led to investigation of the effect of IL-6 on EVT secretion of angiogenic growth factors and cytokines. Although the majority of the secreted proteins analysed were reduced with IL-6 treatment, this was significant only for RANTES. EVT cells penetrate the decidualized endometrium and further migrate within the lumen of spiral arteries to remodel the uterine vasculature. RANTES had been shown to increase migration of isolated macaque trophoblast cells. Thirkill et al. (2005) and Naruse et al. (2010) reported the production of RANTES by both CTB and EVT with an increase between 8 -10 and 12 -14 weeks gestational age; trophoblast secretion of RANTES may play a role in mediating trophoblast migration and IL-6 could play a role in the regulation of this function.
An extensive literature reflects the importance of IL-6 in human implantation and pregnancy, but there is little understanding of the effect of IL-6 on trophoblast function. It has been suggested that IL-6 may contribute to trophoblast growth and development by stimulation of trophoblast-derived hCG (Nishino et al., 1990) , which is essential for the maintenance of pregnancy and may play a role in the differentiation of CTBs in blastocyst implantation. Taniguchi et al. (1992) demonstrated that IL-6 enhanced secretion of hCG by Jar, HCCM-5 choriocarcinoma cell line and BeWo choriocarcinoma cell lines. BeWo cells, in common with EVT and CTB, secrete high levels of RANTES and IL-1b, which in turn increases the secretion of hCG. IL-6 may therefore control secretion of these factors by EVT, hence further increasing hCG secretion to maintain a healthy pregnancy. However, this has not yet been observed using primary EVT.
IL-6 is a pleiotrophic cytokine that has both pro-inflammatory and anti-inflammatory functions; many signalling pathways are affected by IL-6, resulting in more than one biological effect. The developmental Figure 4 Effect of exogenous IL-6 (10 ng/ml) on EVT protein secretion. (A) Illustrates a significant reduction in EVT secretion of RANTES after treatment with IL-6; data from human II FASTQuant (n ¼ 7). No significant difference in the levels of other EVT secreted proteins was observed between untreated and IL-6 treated cells (TH1/2 and angiogenesis FASTQuant arrays; n ¼ 4). Protein levels in treated EVT were normalized to untreated control levels and data are shown as mean fold change. *Denotes significance compared with untreated cells P ¼ 0.03 (Wilcoxon rank test). (B) Reduction in RANTES mRNA expression after EVT cells were treated with IL-6. Data are normalized to control and are shown as mean fold change of DDC t values. *Denotes significance P ¼ 0.05 (Students t-test; n ¼ 4).
processes that are essential for successful early human pregnancy, including EVT invasion, involve a complex network of multiple cytokines and growth factors, with both stimulatory and inhibitory functions. The abundance of IL-6 in human uteroplacental tissues in early pregnancy suggests an important role which may require both in vivo and in vitro approaches to unravel.
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